Patent intelligence · US
US 7374770
Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
Patent details — US 7374770
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 20, 2008
- Expiration
- May 15, 2028
- Applicant
- SkinMedica, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K2800/782, A61K31/13, A61K31/198
Quick answer
US 7374770 (Topical composition for follicular delivery of an ornithine decarboxylase inhibitor) is held by SkinMedica, Inc.. Status: granted. Granted May 20, 2008. Expires May 15, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SkinMedica, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K2800/782, A61K31/13, A61K31/198, A61K47/10, A61K8/39
More from SkinMedica, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12357604
Topical formulations of cannabinoids and use thereof in the treatment of pain
granted -
US 12083229
Ocular drug delivery formulation
granted -
US 12042479
Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
granted -
US 11472840
Acetylcholine receptor-binding peptide
granted -
US 11471534
Chitosan-pluronic complex and nano-carrier comprising same
granted -
US 8361485
Conditioned cell culture medium compositions and methods of use
granted -
US 8268336
Compositions containing aromatic aldehydes and their use in treatments
granted -
US 8246969
Compositions containing aromatic aldehydes and their use in treatments
granted
Frequently asked questions
What is US patent 7374770?
US 7374770 (Topical composition for follicular delivery of an ornithine decarboxylase inhibitor) is held by SkinMedica, Inc.. Status: granted. Granted May 20, 2008. Expires May 15, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7374770?
SkinMedica, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 7374770 expire?
Our index shows an expiration date of May 15, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.